Boehringer Ingelheim inaugurates world-class biopharmaceutical manufacturing facility in China
Boehringer Ingelheim | May 16, 2017
Today, Boehringer Ingelheim inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China). The site, with the first-phase investment of more than €70 million, is the first and only biopharmaceutical facility established by a leading multinational active biopharmaceutical manufacturer in China utilizing mammalian cell culture technology.